MicroVAX Overview
- Year Founded
-
2010
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
MicroVAX General Information
Description
Operator of a clinical biotechnology company intended to develop a cancer vaccine. The company is dedicated to the development of potent vaccines, for treatment and preventive purposes, having applications in the areas of cancer and infectious diseases for which effective solutions have not yet been developed, enabling medical professionals to treat patients in a better way.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Services
Primary Office
- 10900 Univesity Boulevard
- Mason Enterprise Center MS 1J2
- Manassas, VA 20110
- United States
+1 (703) 000-0000
MicroVAX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Jan-2023 | 00000 | Completed | Clinical Trials - Phase 1 | ||
| 2. Angel (individual) | 13-Apr-2015 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 | |
| 1. Angel (individual) | 22-Feb-2011 | $22.5K | $22.5K | Completed | Startup |
MicroVAX Patents
MicroVAX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230241193-A1 | Mrna vaccine design using multiple interacting immuno-stimulatory pathways, for cancer and infectious diseases | Pending | 03-Feb-2022 | 0000000000000 | |
| CA-3073992-A1 | Combination cancer therapy | Pending | 01-Sep-2017 | 000000000000 | |
| US-20190070289-A1 | Combination cancer therapy | Pending | 01-Sep-2017 | 000000000000 | |
| EP-3675891-A4 | Combination cancer therapy | Pending | 01-Sep-2017 | 000000000000 | 0 |
| EP-3675891-A1 | Combination cancer therapy | Pending | 01-Sep-2017 | A61K39/00117 |
MicroVAX Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jacob Frank | Chief Executive Officer, Managing Member & Principal |